In dialogue with Infobae and in a new delivery of Stamboulian Talks, dr. Isabel Cassetti, medical infectóloga (M. N. 55.583), member of the Advisory Committee of the National Programme of Aids and STDS of the Ministry of Health, medical director of Helios Health, medical coordinator of Stamboulian Health Services and chief of service for infectious diseases of the Sanatorio de la Trinidad San Isidro he referred to the present and future of the most promising treatments for the new coronavirus SARS-CoV-2.
According to the expert, “the most important thing is that we know that there are many studies underway, a lot of people in the world to investigate, to give us the best treatment, with higher efficacy and low toxicityminimal, almost nothing.”
“Today we cannot say that we have an optimal treatment for the COVID-19, but know that there are many efforts underway. It’s not worth going to the pharmacy, buy hydroxychloroquine, and take it preemptively, is not shown to its usefulness. There is No evidence that the president, Donald Trump, or Jair Bolsonaro, or whoever take the hydroxychloroquine and that you do well, on the contrary, can be very dangerous, don’t do that, until there is scientific evidence that tell us that we are taking something that will benefit us,” he added.
In the race to find an effective treatment to respond to the pandemic by coronavirus, the World Health Organization (WHO) launched the study Solidarity, which involved more than 90 countries and tested between the existing drugs, one that is safe and effective against the COVID-19, until you design a new molecule, and specific anti-SARS-CoV-2.
In the publication, Christian Funck-Brentano, Joe-Elie Salem Mandeep Mehra and his colleagues reported who administered the drug in 96.032 hospitalized patients (mean age 53,8 years, 46,3% women) who were positive for the COVID-19. The verified data from an international registry, which includes 671 hospitals on six continents were used to compare patients with coronavirus that received chloroquine (1868 patients), hydroxychloroquine (3016 cases), chloroquine with a macrolide (3783 individuals), or hydroxychloroquine, with a macrolide (6221 hospitalized), within 48 hours of the diagnosis of COVID-19, with 81.144 controls known as placebos which did not receive these medications.
The primary outcome was studied on in-hospital mortality and also examined the occurrence of non-sustained ventricular tachycardia, or sustained de novo or ventricular fibrillation.
“If we had COVID and we are healed, it would be nice that we can donate blood, because the plasma that forms part of this compound is being moved to that blood, takes the plasma and has antibodies, the same is transferred to a person who is sick, and that can be extremely useful” said Cassetti.
“With the remdesivir there is a little light, will probably be approved, and be accessible in a short time. For health professionals, we know that there are prevention strategies, hopefully we can soon have in our country. It is important that we care for, to others and among ourselves”, he summed up the infectóloga.
For Cassetti, “the scientific information about various aspects of COVID-19 is a dynamic and changing. In particular, it referred to the treatment, has attracted much interest, following the article published in the scientific journal The Lancet may 22, where he says that hydroxychloroquine does not give any benefit and on the contrary can lead to an increase in mortality and cardiac arrhythmias. The article is deficient weather, and their conclusions can not be extrapolated to the entire universe of patients with COVID-19. WHO take this article and suspend the branch of hydroxychloroquine study Solidarity”.
“It is striking that other studies with a similar design to the Solidarity as the study Recovery have not suspended also the branch of hydroxychloroquine, as neither have been suspended other studies with this drug, which today are ongoing in the world”, warned the medical infectóloga.
According added, “our country, on the 29th of may, took out the Treatment Recommendations of COVID-19 of the Ministry of Health, which recommends that the proposals for the treatment must be given in the context of clinical trials, and not outside of them.”
“I think that in the absence of these trials, in the places of work, there’s always categorize what type of patient are we talking about, age, comorbidities, etc and of course do not expose people to a risk of unnecessary and even dangerousbut do not stop to assess case by case whether there might be some benefit, without causing any risk with the strategy is implemented”, conluyó.
The objective of Stamboulian Talks is to convey through exhibitions attractive and synthetic aspects that are interesting, important, or novel in health issues. The goal is that each presentation will serve as a trigger for the audience to feel motivated to deepen, explore, create awareness or take action in relation to the topics presented.